|
1
|
Zhang J, Chen H, Shi L, Ma Y, Zhi P, Li H, Zhang H, Geng J, Zhang LZ, Jing Y, Lu X. Quantitative transcriptome-based analysis predicts a combination therapy for severe haemophilia B: A case report. Br J Haematol 2024; 204:1105-1108. [PMID: 38148507 DOI: 10.1111/bjh.19261] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2023] [Accepted: 12/02/2023] [Indexed: 12/28/2023]
Affiliation(s)
- Jundong Zhang
- Department of Hematology, Second Medical Center & National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China
| | - Haoran Chen
- School of Management, Shanxi Medical University, Taiyuan, China
| | - Lei Shi
- Senior Department of Infectious Diseases, the Fifth Medical Center & National Clinical Research Center for Infectious Diseases, Chinese PLA General Hospital, Beijing, China
| | - Yanping Ma
- Department of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China
| | - Peng Zhi
- Medical School of Chinese PLA, Beijing, China
- Medical Big Data Research Center, Chinese PLA General Hospital, Beijing, China
| | - Hongyi Li
- Medical School of Chinese PLA, Beijing, China
| | - Haojun Zhang
- Basic Medicine College, Shanxi Medical University, Taiyuan, China
| | - Jie Geng
- Basic Medicine College, Shanxi Medical University, Taiyuan, China
| | - Li Zhong Zhang
- Basic Medicine College, Shanxi Medical University, Taiyuan, China
| | - Yu Jing
- Department of Hematology, Fifth Medical Center, Chinese PLA General Hospital, Beijing, China
| | - Xuechun Lu
- Department of Hematology, Second Medical Center & National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China
- Department of Nephrology, First Medical Center of Chinese PLA General Hospital, Nephrology Institute of the Chinese People's Liberation Army, National Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Kidney Disease Research, Beijing, China
| |
Collapse
|
|
2
|
Abstract
Concizumab (Alhemo™), a subcutaneously administered humanised monoclonal IgG4 antibody against tissue factor pathway inhibitor (TFPI), binds to the Kunitz-2 domain of TFPI and prevents TFPI from binding to activated Factor X. Concizumab is being developed by Novo Nordisk for the treatment of hemophilia A and B with and without inhibitors. In March 2023, concizumab was approved in Canada for the treatment of adolescent and adult patients (12 years of age or older) with hemophilia B who have FIX inhibitors and require routine prophylaxis to prevent or reduce the frequency of bleeding episodes. This article summarizes the milestones in the development of concizumab leading to this first approval for the treatment of hemophilia B.
Collapse
Affiliation(s)
- Susan J Keam
- Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
| |
Collapse
|